Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 153
Filter
1.
Pflugers Arch ; 476(6): 901-909, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38532117

ABSTRACT

Administering sodium bicarbonate (NaHCO3) to patients with respiratory acidosis breathing spontaneously is contraindicated because it increases carbon dioxide load and depresses pulmonary ventilation. Nonetheless, several studies have reported salutary effects of NaHCO3 in patients with respiratory acidosis but the underlying mechanism remains uncertain. Considering that such reports have been ignored, we examined the ventilatory response of unanesthetized dogs with respiratory acidosis to hypertonic NaHCO3 infusion (1 N, 5 mmol/kg) and compared it with that of animals with normal acid-base status or one of the remaining acid-base disorders. Ventilatory response to NaHCO3 infusion was evaluated by examining the ensuing change in PaCO2 and the linear regression of the PaCO2 vs. pH relationship. Strikingly, PaCO2 failed to increase and the ΔPaCO2 vs. ΔpH slope was negative in respiratory acidosis, whereas PaCO2 increased consistently and the ΔPaCO2 vs. ΔpH slope was positive in the remaining study groups. These results cannot be explained by differences in buffering-induced decomposition of infused bicarbonate or baseline levels of blood pH, PaCO2, and pulmonary ventilation. We propose that NaHCO3 infusion improved the ventilatory efficiency of animals with respiratory acidosis, i.e., it decreased their ratio of total pulmonary ventilation to carbon dioxide excretion (VE/VCO2). Such exclusive effect of NaHCO3 infusion in animals with respiratory acidosis might emanate from baseline increased VD/VT (dead space/tidal volume) caused by bronchoconstriction and likely reduced pulmonary blood flow, defects that are reversed by alkali infusion. Our observations might explain the beneficial effects of NaHCO3 reported in patients with acute respiratory acidosis.


Subject(s)
Acidosis, Respiratory , Carbon Dioxide , Sodium Bicarbonate , Animals , Sodium Bicarbonate/pharmacology , Sodium Bicarbonate/administration & dosage , Acidosis, Respiratory/drug therapy , Dogs , Carbon Dioxide/metabolism , Pulmonary Ventilation/drug effects , Hydrogen-Ion Concentration
2.
J Pharmacol Exp Ther ; 388(2): 637-646, 2024 01 17.
Article in English | MEDLINE | ID: mdl-37977816

ABSTRACT

Botulinum neurotoxin (BoNT) is a potent protein toxin that causes muscle paralysis and death by asphyxiation. Treatments for symptomatic botulism are intubation and supportive care until respiratory function recovers. Aminopyridines have recently emerged as potential treatments for botulism. The clinically approved drug 3,4-diaminopyridine (3,4-DAP) rapidly reverses toxic signs of botulism and has antidotal effects when continuously administered in rodent models of lethal botulism. Although the therapeutic effects of 3,4-DAP likely result from the reversal of diaphragm paralysis, the corresponding effects on respiratory physiology are not understood. Here, we combined unrestrained whole-body plethysmography (UWBP) with arterial blood gas measurements to study the effects of 3,4-DAP, and other aminopyridines, on ventilation and respiration at terminal stages of botulism in mice. Treatment with clinically relevant doses of 3,4-DAP restored ventilation in a dose-dependent manner, producing significant improvements in ventilatory parameters within 10 minutes. Concomitant with improved ventilation, 3,4-DAP treatment reversed botulism-induced respiratory acidosis, restoring blood levels of CO2, pH, and lactate to normal physiologic levels. Having established that 3,4-DAP-mediated improvements in ventilation were directly correlated with improved respiration, we used UWBP to quantitatively evaluate nine additional aminopyridines in BoNT/A-intoxicated mice. Multiple aminopyridines were identified with comparable or enhanced therapeutic efficacies compared with 3,4-DAP, including aminopyridines that selectively improved tidal volume versus respiratory rate and vice versa. In addition to contributing to a growing body of evidence supporting the use of aminopyridines to treat clinical botulism, these data lay the groundwork for the development of aminopyridine derivatives with improved pharmacological properties. SIGNIFICANCE STATEMENT: There is a critical need for fast-acting treatments to reverse respiratory paralysis in patients with botulism. This study used unrestrained, whole-body plethysmography and arterial blood gas analysis to show that aminopyridines rapidly restore ventilation and respiration and reverse respiratory acidosis when administered to mice at terminal stages of botulism. In addition to supporting the use of aminopyridines as first-line treatments for botulism symptoms, these data are expected to contribute to the development of new aminopyridine derivatives with improved pharmacological properties.


Subject(s)
Acidosis, Respiratory , Botulinum Toxins, Type A , Botulism , Mice , Humans , Animals , Botulism/drug therapy , Aminopyridines/pharmacology , Amifampridine/therapeutic use , Acidosis, Respiratory/drug therapy , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins, Type A/toxicity , Paralysis/drug therapy , Respiration
3.
J Vet Emerg Crit Care (San Antonio) ; 32(3): 341-349, 2022 May.
Article in English | MEDLINE | ID: mdl-35080109

ABSTRACT

OBJECTIVE: Acidosis decreases myocardial contractile and myofibrillar responsiveness by reducing the calcium sensitivity of contractile proteins, which could reduce the effectiveness of pimobendan. We aimed to assess the cardiovascular effects of pimobendan in dogs subjected to acute respiratory acidosis. DESIGN: Randomized crossover study with a 2-week washout period. SETTING: University Laboratory. ANIMALS: Six healthy research Beagle dogs. INTERVENTIONS: Anesthetized dogs were administered 2 doses of IV pimobendan during conditions of eucapnia (Paco2 35-40 mm Hg) and hypercapnia (Paco2 90-110 mm Hg). Eucapnia was maintained by positive pressure ventilation and hypercapnia was induced by adding exogenous CO2 to the anesthesia circuit. Heart rate (HR), systemic arterial blood pressure, cardiac output (CO), systemic and pulmonary vascular resistance (SVR and PVR, respectively), and pulmonary arterial pressure (PAP) were measured at baseline and 60 min after administering 0.125 mg/kg (low) and 0.25 mg/kg (high) pimobendan intravenously. Blood gas and biochemical analyses were performed at baseline and at the end of the experiment. MEASUREMENTS AND MAIN RESULTS: The median baseline blood pH was 7.41 (range: 7.33-7.45) and 7.03 (range: 6.98-7.09) under conditions of eucapnia and hypercapnia, respectively. The serum concentrations of epinephrine and norepinephrine and the HR, CO, and PAP were higher, and SVR was lower at baseline in hypercapnic dogs. Pimobendan dose-dependently increased CO in eucapnia (baseline: 3.6 ± 0.2 L/kg/m2 [mean ± SE], low: 5.0 ± 0.4 L/kg/m2 , high: 5.8 ± 0.5 L/kg/m2 , P < 0.001) and hypercapnia (baseline: 4.9 ± 0.5 L/kg/m2 , low: 5.8 ± 0.5 L/kg/m2 , high: 6.2 ± 0.5 L/kg/m2 , P < 0.001), and increased HR and decreased SVR and PVR under both conditions (P < 0.001). In hypercapnia, the degree of increase or decrease of these cardiovascular measurements (except for PAP) by pimobendan was less than that in the eucapnic dogs. CONCLUSIONS: Pimobendan maintains function as an inodilator in anesthetized dogs with induced respiratory acidosis.


Subject(s)
Acidosis, Respiratory , Acidosis , Dog Diseases , Animals , Dogs , Acidosis/veterinary , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/veterinary , Cross-Over Studies , Dog Diseases/drug therapy , Hemodynamics , Hypercapnia/veterinary , Pyridazines
4.
Curr Opin Nephrol Hypertens ; 30(2): 223-230, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33395037

ABSTRACT

PURPOSE OF REVIEW: Respiratory acidosis is commonly present in patients with respiratory failure. The usual treatment of hypercapnia is to increase ventilation. During the recent surge of COVID-19, respiratory acidosis unresponsive to increased mechanical ventilatory support was common. Increasing mechanical ventilation comes at the expense of barotrauma and hemodynamic compromise from increasing positive end-expiratory pressures or minute ventilation. Treating acute respiratory acidemia with sodium bicarbonate remains controversial. RECENT FINDINGS: There are no randomized controlled trials of administration of sodium bicarbonate for respiratory acidemia. A recent review concluded that alkali therapy for mixed respiratory and metabolic acidosis might be useful but was based on the conflicting and not conclusive literature regarding metabolic acidosis. This strategy should not be extrapolated to treatment of respiratory acidemia. Low tidal volume ventilation in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) has beneficial effects associated with permissive hypercapnia. Whether the putative benefits will be negated by administration of alkali is not known. Hypercapnic acidosis is well tolerated, with few adverse effects as long as tissue perfusion and oxygenation are maintained. SUMMARY: There is a lack of clinical evidence that administration of sodium bicarbonate for respiratory acidosis has a net benefit; in fact, there are potential risks associated with it.


Subject(s)
Acidosis, Respiratory/drug therapy , Sodium Bicarbonate/therapeutic use , Acidosis, Respiratory/etiology , Acute Disease , COVID-19/complications , COVID-19/therapy , Humans , Respiration, Artificial , SARS-CoV-2
5.
Am J Kidney Dis ; 75(2): 265-271, 2020 02.
Article in English | MEDLINE | ID: mdl-31473018

ABSTRACT

Alkali therapy for certain organic acidoses remains a topic of ongoing controversy, but little attention has been given to a related medical controversy, namely the prescription of alkali for respiratory acidosis. We first describe the determinants of carbon dioxide retention in the 2 types of respiratory failure; hypercapnic respiratory failure and hypoxemic respiratory failure with coexisting hypercapnia. We then highlight the deleterious consequences of severe acidemia for several organ systems, particularly the cardiovascular and central nervous systems. We argue that alkali therapy is not indicated for respiratory acidosis as a simple acid-base disturbance. Notwithstanding, we recommend prescription of alkali for severe acidemia caused by mixed acidosis (ie, combined respiratory and metabolic acidosis) or permissive hypercapnia. We examine the utility of alkali therapy in various clinical scenarios incorporating respiratory acidosis. We conclude that controlled studies will be required to test the impact of alkali therapy on clinical outcomes of these clinical settings. Such studies should also examine the optimal mode of administering alkali (amount, rate, and tonicity) and the blood pH to be targeted. The development of new buffers should be explored, especially systems that do not generate carbon dioxide or even consume it.


Subject(s)
Acidosis, Respiratory/drug therapy , Alkalies/therapeutic use , Carbon Dioxide/blood , Acid-Base Equilibrium , Acidosis, Respiratory/blood , Humans , Treatment Outcome
6.
PLoS One ; 14(7): e0213414, 2019.
Article in English | MEDLINE | ID: mdl-31291253

ABSTRACT

In acidosis, catecholamines are attenuated, and higher doses are often required to improve cardiovascular function. Colforsin activates adenylate cyclase in cardiomyocytes without beta-adrenoceptor. Here, six beagles were administered colforsin or dobutamine four times during eucapnia (partial pressure of arterial carbon dioxide 35-40 mm Hg; normal) and hypercapnia (ibid 90-110 mm Hg; acidosis) conditions. The latter was induced by CO2 inhalation. Anesthesia was induced with propofol and maintained with isoflurane. Cardiovascular function was measured by thermodilution and a Swan-Ganz catheter at baseline and 60 min after 0.3 µg/kg/min (low), 0.6 µg/kg/min (middle), and 1.2 µg/kg/min (high) colforsin administration. The median pH was 7.38 [range 7.33-7.42] and 7.01 [range 6.96-7.08] at baseline in the Normal and Acidosis conditions, respectively. Endogenous adrenaline and noradrenaline levels at baseline were significantly (P < 0.05) higher in the Acidosis than in the Normal condition. Colforsin induced cardiovascular effects similar to those caused by dobutamine. Colforsin increased cardiac output in the Normal condition (baseline: 3.9 ± 0.2 L/kg/m2 [mean ± standard error], low: 5.2 ± 0.4 L/kg/min2, middle: 7.0 ± 0.4 L/kg/m2, high: 9.4 ± 0.2 L/kg/m2; P < 0.001) and Acidosis condition (baseline: 6.1 ± 0.3 L/kg/m2, low: 6.2 ± 0.2 L/kg/m2, middle: 7.2 ± 0.2 L/kg/m2, high: 8.3 ± 0.2 L/kg/m2; P < 0.001). Colforsin significantly increased heart rate and decreased systemic vascular resistance compared to values at baseline. Both drugs increased pulmonary artery pressure, but colforsin (high: 13.3 ± 0.6 mmHg in Normal and 20.1 ± 0.2 mmHg in Acidosis) may have lower clinical impact on the pulmonary artery than dobutamine (high: 19.7 ± 0.6 in Normal and 26.7 ± 0.5 in Acidosis). Interaction between both drugs and experimental conditions was observed in terms of cardiovascular function, which were similarly attenuated with colforsin and dobutamine under acute respiratory acidosis.


Subject(s)
Acidosis, Respiratory/drug therapy , Cardiotonic Agents/administration & dosage , Colforsin/analogs & derivatives , Acidosis, Respiratory/physiopathology , Animals , Blood Pressure/drug effects , Cardiac Output/drug effects , Catecholamines/blood , Colforsin/administration & dosage , Disease Models, Animal , Dobutamine/administration & dosage , Dogs , Dose-Response Relationship, Drug , Female , Heart Rate/drug effects , Male , Pulmonary Artery/drug effects , Pulmonary Artery/physiopathology , Vascular Resistance/drug effects
7.
Med. intensiva (Madr., Ed. impr.) ; 43(4): 234-242, mayo 2019. graf
Article in Spanish | IBECS | ID: ibc-183128

ABSTRACT

En los últimos años han surgido importantes descubrimientos sobre el papel del dióxido de carbono (CO2) a nivel celular y molecular, y sobre los efectos de la hipercapnia. Esta última puede tener efectos beneficiosos en pacientes con patología pulmonar aguda, como la reducción de la inflamación pulmonar y del daño oxidativo alveolar, la regulación de la inmunidad innata, la defensa del huésped y la inhibición de la expresión de citoquinas inflamatorias. Sin embargo, otros estudios sugieren que el CO2 puede tener efectos nocivos en el pulmón, como retraso en la reparación alveolar tras la injuria pulmonar, disminución de las tasas de reabsorción del fluido alveolar e inhibición de la proliferación de células alveolares. Por lo tanto, la hipercapnia tiene efectos tanto beneficiosos como nocivos y es importante determinar el efecto neto en condiciones específicas. El propósito de esta revisión es describir los efectos fisiológicos e inmunomoduladores de la hipercapnia, considerando sus potenciales consecuencias en el paciente con insuficiencia respiratoria aguda


Important recent insights have emerged regarding the cellular and molecular role of carbon dioxide (CO2) and the effects of hypercapnia. The latter may have beneficial effects in patients with acute lung injury, affording reductions in pulmonary inflammation, lessened oxidative alveolar damage, and the regulation of innate immunity and host defenses by inhibiting the expression of inflammatory cytokines. However, other studies suggest that CO2 can have deleterious effects upon the lung, reducing alveolar wound repair in lung injury, decreasing the rate of reabsorption of alveolar fluid, and inhibiting alveolar cell proliferation. Clearly, hypercapnia has both beneficial and harmful consequences, and it is important to determine the net effect under specific conditions. The purpose of this review is to describe the immunological and physiological effects of carbon dioxide, considering their potential consequences in patients with acute respiratory failure


Subject(s)
Humans , Carbon Dioxide/therapeutic use , Critical Care , Hypercapnia/drug therapy , Carbon Dioxide/adverse effects , Respiratory Insufficiency/complications , Respiratory Insufficiency/drug therapy , Respiration, Artificial/adverse effects , Acidosis, Respiratory/drug therapy
9.
J Emerg Med ; 54(5): 615-618, 2018 05.
Article in English | MEDLINE | ID: mdl-29482923

ABSTRACT

BACKGROUND: Critical central airway obstruction (CAO) requires emergent airway intervention, but current guidelines lack specific recommendations for airway management in the emergency department (ED) while awaiting rigid bronchoscopy. There are few reports of the use of noninvasive ventilation (NIV) in tracheomalacia, but its use as a temporizing treatment option in fixed, malignant CAO has not, to the best of our knowledge, been reported. CASE REPORT: An 84-year-old woman presented to the ED in respiratory distress, too breathless to speak and using her accessory muscles of respiration, with bilateral rhonchi throughout the lung fields. Point-of-care arterial blood gas revealed severe hypercapnia, and NIV was initiated to treat a presumed bronchitis with hypercapnic respiratory failure. Chest radiography revealed a paratracheal mass with tracheal deviation and compression. A diagnosis of critical CAO was made. While arranging for rigid bronchoscopic stenting, the patient was kept on NIV to good effect. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Recommendations for emergent treatment of life-threatening, critical CAO before bronchoscopic intervention are not well established. Furthermore, reports of NIV use in CAO are rare. We suggest that emergency physicians consider NIV as a temporizing measure for critical CAO while awaiting availability of bronchoscopy.


Subject(s)
Airway Obstruction/classification , Airway Obstruction/therapy , Noninvasive Ventilation/standards , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/etiology , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Blood Gas Analysis/methods , Female , Humans , Levofloxacin/therapeutic use , Noninvasive Ventilation/methods , Radiography/methods
10.
Zhong Nan Da Xue Xue Bao Yi Xue Ban ; 43(11): 1177-1181, 2018 Nov 28.
Article in Chinese | MEDLINE | ID: mdl-30643060

ABSTRACT

OBJECTIVE: To establish rat model of lung ischemia/reperfusion (IR) in vivo, and to explore the effects of acidification pretreatment for respiratory acidosis on the expression of matrix metalloproteinase-9 (MMP-9) and the possible mechanisms.
 Methods: A total of 36 male Sprague-Dawley rats were divided into a sham group (S group), a IR group, and an experiment group (RA group) (n=12 in each group). The rat left lung hilum in the S group was dissociated, followed by perfusion without ischemia. After the left lung hilum in the IR group was blocked for 45 min, the rats were followed by reperfusion for 180 min. After left lung hilum in the RA group was dissociated, the respiratory parameters were adjusted so that pressure of end tidal carbon dioxide (PETCO2) reached 56-65 mmHg (1 mmHg=0.133 kPa) for 5 min, then the rats was subjected to IR. Lung tissue wet/dry (W/D) and lung permeability index (LPI) were calculated, while the lung histopathology was observed and the MMP-9 protein expression were measured.
 Results: Compared with the control group, the W/D and LPI in the IR group and the RA group increased after reperfusion (both P<0.05), and the levels of W/D and LPI in the group RA were lower than that in the IR group (P<0.05). LPI and pathology scores were significantly lower in the RA group than those in the IR group (both P<0.01). After IR, the expression of MMP9 in the lung tissues in the IR group and the RA group increased significantly (both P<0.01). The expression of MMP-9 protein in the RA group was significantly lower than that in the IR group (P<0.01).
 Conclusion: After lung IR injury, the expression of MMP-9 protein, vascular permeability and inflammatory exudation is increased. The acidification pretreatment for respiratory acidosis can inhibit the expression of MMP-9 protein and reduce inflammatory exudation after lung IR, showing a protective effect on lung IR injury.


Subject(s)
Acidosis, Respiratory , Lung/enzymology , Matrix Metalloproteinase 9 , Reperfusion Injury/prevention & control , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/prevention & control , Animals , Gene Expression Regulation, Enzymologic/drug effects , Lung Injury/enzymology , Male , Matrix Metalloproteinase 9/genetics , Rats , Rats, Sprague-Dawley , Reperfusion Injury/drug therapy
11.
ASAIO J ; 61(5): 533-9, 2015.
Article in English | MEDLINE | ID: mdl-26273934

ABSTRACT

Acidification of blood entering a membrane lung (ML) with lactic acid enhances CO2 removal (VCO2ML). We compared the effects of infusion of acetic, citric, and lactic acids on VCO2ML. Three sheep were connected to a custom-made circuit, consisting of a Hemolung device (Alung Technologies, Pittsburgh, PA), a hemofilter (NxStage, NxStage Medical, Lawrence, MA), and a peristaltic pump recirculating ultrafiltrate before the ML. Blood flow was set at 250 ml/min, gas flow (GF) at 10 L/min, and recirculating ultrafiltrate flow at 100 ml/min. Acetic (4.4 M), citric (0.4 M), or lactic (4.4 M) acids were infused in the ultrafiltrate at 1.5 mEq/min, for 2 hours each, in randomized fashion. VCO2ML was measured by the Hemolung built-in capnometer. Circuit and arterial blood gas samples were collected at baseline and during acid infusion. Hemodynamics and ventilation were monitored. Acetic, citric, or lactic acids similarly enhanced VCO2ML (+35%), from 37.4 ± 3.6 to 50.6 ± 7.4, 49.8 ± 5.6, and 52.0 ± 8.2 ml/min, respectively. Acids similarly decreased pH, increased pCO2, and reduced HCO3 of the post-acid extracorporeal blood sample. No significant effects on arterial gas values, ventilation, or hemodynamics were observed. In conclusion, it is possible to increase VCO2ML by more than one-third using any one of the three metabolizable acids.


Subject(s)
Acidosis, Respiratory/blood , Calcium/blood , Carbon Dioxide/blood , Carboxylic Acids/pharmacology , Extracorporeal Circulation/methods , Respiration, Artificial/methods , Acetic Acid/metabolism , Acetic Acid/pharmacology , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/surgery , Animals , Blood Gas Analysis , Calcium/metabolism , Carbon Dioxide/metabolism , Citric Acid/metabolism , Citric Acid/pharmacology , Female , Hemodynamics , Lactic Acid/metabolism , Lactic Acid/pharmacology , Sheep
12.
Int J Immunopathol Pharmacol ; 25(2): 493-7, 2012.
Article in English | MEDLINE | ID: mdl-22697081

ABSTRACT

Bronchiolitis is a lower respiratory tract viral infection which may result in severe bronchial obstruction and respiratory failure despite treatment with beta-adrenergic agonists and glucocorticoids. Here we describe two otherwise healthy infants with severe bronchiolitis whose clinical course was complicated by marked bronchial obstruction and respiratory acidosis refractory to conventional medications (ß-stimulants, anticholinergics and corticosteroids) and non-invasive positive pressure ventilation. Sevoflurane inhalation allowed both infants to attain a sustained, clinical improvement in ventilation and one patient to avoid mechanical ventilation. We suggest that sevoflurane inhalation may be a therapeutic option in the treatment of young infants with severe bronchiolitis who respond poorly to conventional therapy.


Subject(s)
Bronchiolitis/drug therapy , Bronchodilator Agents/administration & dosage , Methyl Ethers/administration & dosage , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/etiology , Administration, Inhalation , Airway Obstruction/drug therapy , Airway Obstruction/etiology , Bronchiolitis/complications , Bronchiolitis/diagnosis , Humans , Infant , Male , Respiration, Artificial , Severity of Illness Index , Sevoflurane , Treatment Outcome
13.
Arch Bronconeumol ; 48(10): 349-54, 2012 Oct.
Article in English, Spanish | MEDLINE | ID: mdl-22705258

ABSTRACT

OBJECTIVE: To determine the usefulness of non-invasive ventilation (NIV) in elderly patients (≥75) admitted to a respiratory monitoring unit (RMU) during hospitalization and 1 year later in comparison with the results from the younger age group (<75). MATERIAL AND METHODS: Ours is a prospective observational study carried out at the Hospital Universitario La Princesa (Madrid, Spain). We recruited all patients who were ≥75 years old and were admitted to our RMU during the period 2008-2009 with respiratory acidosis (pH<7.35 and PaCO(2)>45 mmHg) requiring NIV. We gathered data for basic variables as well as sociodemographics, history of previous pathologies, reason for hospitalization and severity, analysis upon admission and the evolution of blood gases at the start of NIV (within the first hour and after 24 h), complications and evolution at the 1-year follow-up. RESULTS: Mean age of the sample was 80.6. The Charlson index was 3.27. About half of the patients had some limitation for performing daily activities. The main reasons for admission were COPD exacerbation and heart failure. There were complications in 36% of the cases (11 renal failure and 6 atrial fibrillation). The survival rate at the 1-year follow-up was 63.21%. CONCLUSIONS: NIV is a good alternative in elderly patients admitted to the hospital with respiratory acidosis. We did not detect differences in mortality during admission between the two groups. The elderly patients were more frequently re-admitted than the younger group in the 6-12 months after hospital discharge. This could be due to their poorer functional state after hospitalization requiring NIV.


Subject(s)
Acidosis, Respiratory/therapy , Noninvasive Ventilation , Respiratory Care Units , Acidosis, Respiratory/blood , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/etiology , Activities of Daily Living , Age Factors , Aged , Aged, 80 and over , Combined Modality Therapy , Disease Management , Female , Follow-Up Studies , Heart Failure/complications , Hospital Mortality , Humans , Kidney Failure, Chronic/complications , Male , Noninvasive Ventilation/statistics & numerical data , Oxygen/blood , Oxygen Inhalation Therapy , Patient Readmission/statistics & numerical data , Prospective Studies , Pulmonary Disease, Chronic Obstructive/complications , Respiratory Care Units/statistics & numerical data , Spain/epidemiology , Tertiary Care Centers/statistics & numerical data , Vasoconstrictor Agents/therapeutic use
14.
Neonatology ; 99(3): 170-6, 2011.
Article in English | MEDLINE | ID: mdl-20798555

ABSTRACT

BACKGROUND: Birth asphyxia is characterized by intermittent periods of hypoxia/ischemia leading to metabolic acidosis. The use of intravenous sodium bicarbonate (IVSB) is still a matter of controversy in clinical practice. OBJECTIVE: To assess the use of IVSB in birth asphyxia by attending neonatologists in European hospitals. DESIGN/METHODS: Survey using a questionnaire administered to neonatologists in Europe whose electronic addresses were provided by the national councils of neonatology of each participating country. The questionnaire consisted of a brief theoretical introduction followed by demographic questions related to the respondent's professional qualification. This was followed by a clinical case of an asphyxiated term neonate with severe combined metabolic and respiratory acidosis and case-specific questions related to the perceived indication for administration of IVSB and use of additional therapies to address the clinical situation. Descriptive statistics and χ² analysis were performed. RESULTS: The questionnaire was answered by 259 neonatologists from 17 countries. IVSB was believed to be indicated by 109 (42.2%) of the respondents in this clinical scenario. Results differed significantly between countries, with IVSB use varying from as high as 68% in Portugal and <5% in Scandinavian countries. However, there were no differences in the choice of other therapeutic measures. CONCLUSIONS: Although scientific evidence suggests that IVSB is not effective in asphyxiated newborns and current guidelines do not recommend its use, 42.2% of the consulted neonatologists in Europe would use it, with significant differences between but not within countries. There were no differences regarding additional measures to overcome asphyxia. Strategies to implement use of internationally accepted guidelines are needed.


Subject(s)
Asphyxia Neonatorum/drug therapy , Sodium Bicarbonate/administration & dosage , Acidosis/drug therapy , Acidosis/metabolism , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/metabolism , Asphyxia Neonatorum/metabolism , Europe , Humans , Infant, Newborn , Infusions, Intravenous , Practice Patterns, Physicians' , Surveys and Questionnaires
15.
Pediatr Pulmonol ; 45(8): 782-8, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20597076

ABSTRACT

OBJECTIVE: To determine the effectiveness of artificial surfactant therapy using KL-4 surfactant in newborn pigs with hydrochloric acid (HCl)-induced acute lung injury (ALI). DESIGN: After induction of ALI via intratracheal HCl instillation, pigs were randomized to receive 5.8 ml/kg KL-4 surfactant or no surfactant prior to extubation to bubble CPAP. SETTING: Clinical laboratory. SUBJECTS: Spontaneously breathing newborn pigs (<1 week of age). INTERVENTIONS: Treatment with KL-4 surfactant on bubble CPAP with PEEP of 6 cmH(2)O for 3.5 hr after extubation compared with controls. MEASUREMENTS: Physiologic parameters and arterial blood gases were measured every 15 min. At the conclusion of the study, the lungs were excised for the analysis of histopathology and morphometric data. MAIN RESULTS: Pigs treated with KL-4 surfactant had arterial blood gases with less acidosis (P < 0.001), higher P(a)O(2) levels (P < 0.001), and lower P(a)CO(2) levels (P < 0.001). Pigs treated with KL-4 surfactant had improved survival compared with controls (6/12 KL-4, 2/12 control, P < 0.05). Postmortem morphometric data demonstrated that pigs treated with KL-4 surfactant had larger (P < 0.05) exchange units in the caudal-dorsal lung as compared to relatively atelectatic region in the control animals. CONCLUSIONS: In newborn pigs with severe HCl-induced ALI, treatment with KL-4 surfactant resulted in improved respiratory parameters, less dependent atelectasis, and improved short-term survival.


Subject(s)
Acute Lung Injury/drug therapy , Peptides/therapeutic use , Pulmonary Gas Exchange/drug effects , Acidosis, Respiratory/drug therapy , Acute Lung Injury/mortality , Acute Lung Injury/pathology , Animals , Animals, Newborn , Blood Gas Analysis , Disease Models, Animal , Intercellular Signaling Peptides and Proteins , Positive-Pressure Respiration , Pulmonary Atelectasis/drug therapy , Severity of Illness Index , Swine
16.
QJM ; 103(8): 573-81, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20511258

ABSTRACT

BACKGROUND: Drug treatments for acute cardiogenic pulmonary oedema (ACPO) have not been rigorously evaluated and recent observational data suggests some agents are related to poorer outcome. AIM: We aimed to examine the effect of treatment with diuretics, nitrates and opiates on 7-day mortality, acidosis and respiratory distress in UK Emergency Department (ED) patients with severe acidotic pulmonary oedema. DESIGN: Analysis of data from the 3CPO trial; a multicentre randomized controlled trial. METHODS: Data were analysed from patients recruited with severe acidotic pulmonary oedema to the 3CPO trial in 26 UK EDs between 2003 and 2007. The effects of these treatments on 7-day mortality, improvement in acidosis (pH change between baseline and 1 h) and improvement in respiratory distress (patient measured breathlessness using a Visual Analogue Score between baseline and 1 h) were tested using univariate logistic regression analysis, and a regression model used to adjust for confounding baseline differences. RESULTS: Nitrates were given to 947/1048 (90.4%) patients, diuretics to 934/1049 (89.0%) patients and opiates to 541/1052 patients (51.4%). Adjusted analysis showed that opiate treatment was associated with less improvement in acidosis [difference in improvement in pH -0.022, 95% confidence interval (CI) -0.014 to -0.030, P < 0.001], but no difference in mortality or improvement in respiratory distress. We found no evidence that nitrate or diuretic use were associated with any difference in mortality, improvement in acidosis or respiratory distress. CONCLUSION: Opiate use is associated with less improvement in acidosis during initial treatment and may attenuate effective treatment of severe acidotic ACPO.


Subject(s)
Acidosis, Respiratory/drug therapy , Analgesics, Opioid/therapeutic use , Diuretics/therapeutic use , Heart Failure/drug therapy , Nitrates/therapeutic use , Pulmonary Edema/drug therapy , Acidosis, Respiratory/etiology , Acute Disease , Aged , Aged, 80 and over , Algorithms , Emergency Service, Hospital , Female , Heart Failure/complications , Heart Failure/mortality , Humans , Logistic Models , Male , Pulmonary Edema/complications , Pulmonary Edema/mortality , Treatment Outcome , United Kingdom
17.
Crit Care Med ; 37(11): 2953-61, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19773647

ABSTRACT

OBJECTIVE: Prolonged hypercapnia is commonly encountered during the treatment of acute respiratory distress syndrome and acute respiratory failure attributable to other causes with protective ventilation strategies. In these circumstances, compensatory renal buffering returns pH to normal establishing a condition of buffered hypercapnia. It is also common intensive care practice to correct the pH more rapidly using bicarbonate infusions. Although it is well-established that hypercapnic acidosis has potent anti-inflammatory and protective effects, the effect of buffered hypercapnia on acute lung injury and acute respiratory distress syndrome is unknown. We therefore wished to determine the effects of buffered hypercapnia on acute lung injury induced by endotoxin or Escherichia coli infection in vivo. DESIGN: Prospective, randomized animal study. SETTING: University research laboratory. SUBJECTS: Adult male Sprague-Dawley rats. INTERVENTIONS: We established buffered hypercapnia by exposing rats to a hypercapnic environment for 3 days before the induction of lung injury. Buffered hypercapnia rats (initial pH >7.35, FiCO2 = 0.05) and normocapnic controls (initial pH >7.35, FiCO2 = 0.00) were then anesthetized, mechanically ventilated, and lung injury induced by intra-tracheal inoculation of endotoxin (series I) or Escherichia coli (series II). MEASUREMENTS AND MAIN RESULTS: Buffered hypercapnia significantly increased both endotoxin and Escherichia coli-induced lung injury when compared to normocapnic controls, as assessed by arterial oxygenation, lung compliance, pro-inflammatory pulmonary cytokine concentrations, and measurements of structural lung damage. In additional in vitro experiments buffered hypercapnia did not alter neutrophil phagocytosis ability but did impaired epithelial wound healing. CONCLUSIONS: Our results demonstrate that infection-induced injury in vivo is worsened after renal buffering of hypercapnic acidosis independently of any changes in tidal volume. These findings have important implications for our understanding of the pathogenesis of infection-induced lung injury during the use protective ventilation strategies that permits buffered hypercapnia and during infective exacerbations of chronic lung diseases associated with sustained hypercapnia.


Subject(s)
Acidosis, Respiratory/drug therapy , Acute Lung Injury/complications , Escherichia coli Infections/complications , Hypercapnia/complications , Acidosis, Respiratory/complications , Acute Lung Injury/microbiology , Animals , Buffers , Endotoxins/adverse effects , Hydrogen-Ion Concentration , In Vitro Techniques , Male , Neutrophils , Phagocytosis , Prospective Studies , Random Allocation , Rats , Rats, Sprague-Dawley , Sodium Bicarbonate/administration & dosage , Wound Healing
18.
Ann Fr Anesth Reanim ; 28(1): 82-5, 2009 Jan.
Article in French | MEDLINE | ID: mdl-19144494

ABSTRACT

We report the case of a severe acute asthma, which required, after optimal medical therapy, helium and sevoflurane CO-administration after tracheal intubation. The Anesthetic Conserving Device allowed sevoflurane use with intensive care unit's ventilator. The helium-sevoflurane association was maintained during 9 days to decrease the bronchospasm, waiting for the efficiency of an aetiologic treatment. We discuss the suitability of this association to treat severe acute asthma, and its administration modalities.


Subject(s)
Anesthetics, Inhalation/therapeutic use , Asthma/drug therapy , Helium/therapeutic use , Methyl Ethers/therapeutic use , Acidosis, Respiratory/drug therapy , Acidosis, Respiratory/etiology , Acute Disease , Anesthetics, Inhalation/administration & dosage , Bronchial Spasm/drug therapy , Drug Combinations , Female , Helium/administration & dosage , Humans , Hypercapnia/blood , Intubation, Intratracheal , Methyl Ethers/administration & dosage , Middle Aged , Sevoflurane , Ventilators, Mechanical
19.
Am J Vet Res ; 68(12): 1407-16, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18052748

ABSTRACT

OBJECTIVE: To determine and compare the effects of caffeine and doxapram on cardiorespiratory variables in foals during isoflurane-induced respiratory acidosis. ANIMALS: 6 clinically normal foals (1 to 3 days old). PROCEDURES: At intervals of > or = 24 hours, foals received each of 3 IV treatments while in a steady state of hypercapnia induced by isoflurane anesthesia (mean +/- SD, 1.4 +/- 0.3% endtidal isoflurane concentration). After assessment of baseline cardiorespiratory variables, a low dose of the treatment was administered and variables were reassessed; a high dose was then administered, and variables were again assessed. Sequential low- and high-dose treatments included doxapram (loading dose of 0.5 mg/kg, followed by a 20-minute infusion at 0.03 mg/kg/min and then 0.08 mg/kg/min), caffeine (5 mg/kg and 10 mg/kg), and saline (0.9% NaCl) solution (equivalent volumes). RESULTS: Administration of doxapram at both infusion rates resulted in a significant increase in respiratory rate, minute ventilation, arterial blood pH, PaO(2), and arterial blood pressure. These variables were also significantly higher during doxapram administration than during caffeine or saline solution administration. There was a significant dose-dependent decrease in PaCO(2) and arterial bicarbonate concentration during doxapram treatment. In contrast, PaCO(2) increased from baseline values after administration of saline solution or caffeine. The PaCO(2) value was significantly lower during doxapram treatment than it was during caffeine or saline solution treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that doxapram restored ventilation in a dose-dependent manner in neonatal foals with isoflurane-induced hypercapnia. The effects of caffeine on respiratory function were indistinguishable from those of saline solution.


Subject(s)
Acidosis, Respiratory/veterinary , Caffeine/therapeutic use , Central Nervous System Stimulants/therapeutic use , Doxapram/therapeutic use , Acidosis, Respiratory/chemically induced , Acidosis, Respiratory/drug therapy , Anesthetics, Inhalation/adverse effects , Animals , Dose-Response Relationship, Drug , Horses , Isoflurane/adverse effects
20.
Am J Vet Res ; 68(8): 850-7, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17669025

ABSTRACT

OBJECTIVE: To determine concentrations of electrolytes, total bilirubin, urea, creatinine, and hemoglobin; activities of some enzymes; and Hct and number of leukocytes and erythrocytes of newborn calves in relation to the degree of acidosis and treatment with a hypertonic sodium bicarbonate (NaHCO(3)) solution. ANIMALS: 20 acidotic newborn calves with a blood pH < 7.2 and 22 newborn control calves with a blood pH > or = 7.2. PROCEDURES: Approximately 10 minutes after birth, acidotic calves were treated by IV administration of 5% NaHCO(3) solution. The amount of hypertonic solution infused was dependent on the severity of the acidosis. RESULTS: Treatment resulted in a significant increase in the mean +/- SEM base excess from -8.4 +/- 1.2 mmol/L immediately after birth to 0.3 +/- 1.1 mmol/L 120 minutes later. During the same period, sodium concentration significantly increased from 145.3 +/- 0.8 mmol/L to 147.8 +/- 0.7 mmol/L. Mean chloride concentration before NaHCO(3) administration was significantly lower in the acidotic calves (99.6 +/- 1.1 mmol/L) than in the control calves (104.1 +/- 0.9 mmol/L). Calcium concentration in acidotic calves decreased significantly from before to after treatment. Concentrations of potassium, magnesium, and inorganic phosphorus were not affected by treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Administration of hypertonic NaHCO(3) solution to acidotic neonatal calves did not have any adverse effects on plasma concentrations of several commonly measured electrolytes or enzyme activities. The treatment volume used was smaller, compared with that for an isotonic solution, which makes it more practical for use in field settings.


Subject(s)
Acidosis, Lactic/veterinary , Acidosis, Respiratory/veterinary , Animals, Newborn , Cattle Diseases/drug therapy , Electrolytes/metabolism , Sodium Bicarbonate/therapeutic use , Acidosis, Lactic/blood , Acidosis, Lactic/drug therapy , Acidosis, Respiratory/blood , Acidosis, Respiratory/drug therapy , Animals , Cattle , Cattle Diseases/blood , Cattle Diseases/metabolism , Female , Male , Osmolar Concentration , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...